Presentation is loading. Please wait.

Presentation is loading. Please wait.

Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic.

Similar presentations


Presentation on theme: "Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic."— Presentation transcript:

1 Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells  Antonia M.S. Müller, Holbrook E.K. Kohrt, Steven Cha, Ginna Laport, Jared Klein, Alice E. Guardino, Laura J. Johnston, Keith E. Stockerl-Goldstein, Elie Hanania, Christopher Juttner, Karl G. Blume, Robert S. Negrin, Irving L. Weissman, Judith A. Shizuru  Biology of Blood and Marrow Transplantation  Volume 18, Issue 1, Pages (January 2012) DOI: /j.bbmt Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Comparison of fold depletion of cancer cells from MPB using CD34 with and without Thy-1 as positive selecting markers for high-speed cell sorting (FACS) as compared with CD34 magnetic bead selection alone. MPB products were purposefully contaminated with tumor cells, and the selected products were analyzed by an immunoflouresence (IFM) assay for breast cancer. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 Progression-free survival (PFS) (A) and overall survival (OS) (B) in patients undergoing HCT with purified HSC (n = 22; gray) versus unmanipulated mobilized peripheral blood (black). Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

4 Figure 3 OS of 22 recipients of purified HSC (gray) as compared to the cohort given MPB, subdivided into patients with (A) estrogen receptor (ER)-positive and ER-negative breast cancer; (B) relapsed breast cancer or patients with newly diagnosed metastatic disease undergoing auto-HCT as part of their upfront treatment; (C) visceral metastasis versus bone, but no visceral metastasis versus local recurrence versus exclusively lymph node disease; (D) complete response (CR), partial response (PR), or stable or progressive disease (SD/PD). Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions


Download ppt "Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic."

Similar presentations


Ads by Google